Gsk (GSK) Non-Current Deferred Tax Liability (2009 - 2026)
Gsk (GSK) posted quarterly Non-Current Deferred Tax Liability of -$406.5 million for Q2 2026, up 20.64% year-over-year from -$337.0 million in Q2 2025, and down 3.27% quarter-over-quarter from -$393.7 million in Q1 2026.
Gsk (GSK) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Gsk's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at -$406.5 million for Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability rose 20.64% year-over-year to -$406.5 million; the TTM figure through Jun 2026 stood at -$406.5 million (up 20.64% YoY), while the FY2025 annual figure was -$383.7 million, down 178.58% from the prior year.
- Non-Current Deferred Tax Liability for Q2 2026 stood at -$406.5 million, down from -$393.7 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $490.3 million in Q4 2024, with the low at -$4.7 billion in Q1 2022.
- The 5-year median for Non-Current Deferred Tax Liability is -$390.4 million (2025), against an average of -$522.0 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability soared 96.26% in 2022, then tumbled 233.45% in 2023.
- Gsk's Non-Current Deferred Tax Liability stood at $339.0 million in 2022, then climbed by 13.87% to $386.0 million in 2023, then advanced by 27.02% to $490.3 million in 2024, then slumped by 178.95% to -$387.1 million in 2025, then fell by 5.02% to -$406.5 million in 2026.
- Business Quant data shows GSK's Non-Current Deferred Tax Liability at -$406.5 million in Q2 2026, -$393.7 million in Q1 2026, and -$387.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -406.53 Mn |
| Jun 30, 2026 | -406.53 Mn |
| Mar 31, 2026 | -393.67 Mn |
| Mar 31, 2026 | -393.67 Mn |
| Dec 31, 2025 | -387.08 Mn |
| Dec 31, 2025 | -387.08 Mn |
| Sep 30, 2025 | -526.25 Mn |
| Sep 30, 2025 | -526.25 Mn |
| Jun 30, 2025 | -512.27 Mn |
| Jun 30, 2025 | -512.27 Mn |
| Mar 31, 2025 | -508.84 Mn |
| Mar 31, 2025 | -508.84 Mn |
| Dec 31, 2024 | 490.30 Mn |
| Dec 31, 2024 | 490.30 Mn |
| Sep 30, 2024 | -381.99 Mn |
| Sep 30, 2024 | -381.99 Mn |
| Jun 30, 2024 | -366.04 Mn |
| Jun 30, 2024 | -366.04 Mn |
| Mar 31, 2024 | -365.33 Mn |
| Mar 31, 2024 | -365.33 Mn |